Tandem mass spectrometry has been the main driver behind a significant expansion in newborn screening programs. The ability to detect more than 40 conditions by a single test underscores the need to better understand the clinical and laboratory characteristics of the conditions being tested, and the complexity of pattern recognition and differential diagnoses of one or more elevated markers. The panel of conditions recommended by the American College of Medical Genetics, including 20 primary conditions and 22 secondary targets that are detectable by tandem mass spectrometry has been adopted as the standard of care in the vast majority of US states. The evolution of newborn screening is far from being idle as a large number of infectious, genetic, and metabolic conditions are currently under investigation at variable stages of test development and clinical validation. In the US, a formal process with oversight by the Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children has been established for nomination and evidence-based review of new candidate conditions. If approved, these conditions could be added to the uniform panel and consequently pave the way to large scale implementation.
Critical evidence in support of this expansion came from a report released by an expert panel assembled by the American College of Medical Genetics (ACMG) [6, 7] . This report described the evidence-review process applied to identify a panel of 29 conditions, 20 of them screened for by MS/MS analysis, which is commonly referred to as the 'uniform panel'. An additional 25 conditions, 22 of them also detected by MS/MS, were recommended in a cohort of secondary targets. Table 1 shows a list of these 42 conditions, the number of US states currently screening for each of them, and highlights the need for differential diagnosis due to pervasive overlap of informative markers between primary and secondary targets.
To date (July 2007), screening by MS/MS is provided by 48 of 51 US states (including the District of Columbia), a proportion that translates into approximately 98% of the total number of births per year [8] . However, the extent of implementation of the full panel remains variable ( fig. 1 ), ranging between 5 and 100% (5 states) with an overall average of 75%. Although the uniform panel (20 conditions) has been implemented by a majority of states (38 of 51), only six are pursuing the whole set of secondary targets [8] . The inclusion of the secondary targets has been controversial because in most cases their natural history is poorly understood [9] . However, a defining characteristic of a multiplex platform like MS/MS is the need to perform an extensive post-analytical interpretation and differential diagnosis for most of the metabolites detectable in the amino acid and acylcarnitine profiles [4, 10] . If conditions were to be removed from the list of secondary targets on the sole basis of not requiring a differential diagnosis from a primary condition, only argininemia and 2,4-dienoyl-CoA reductase deficiency would be candidates for exclusion from the panel [10, 11] . Limited appreciation of this reality may lead to unfortunate yet fully avoidable situations, for example the reporting of concurrent diagnoses in a patient with a complex biochemical phenotype, or the assumption that a nominal mass represents only one of several possible isobaric compounds [12, 13] . Moreover, advocates of testing by multiple reaction monitoring rather than the full scan mode, for the purpose of avoiding 'undesirable' findings, apparently fail to recognize the number of potentially misleading findings [14, 15] which can only be recognized properly when the full profile is evaluated.
The impact of a deliberate exclusion of informative markers could be as high as missing approximately 10% of all cases who could be detected if the uniform panel was universally implemented ( fig. 2 ). This estimate is extrapolated from an analysis of: (a) current state panels [1, 8] ; (b) incidence data from multiple sources [11, [16] [17] [18] [19] [20] , and (c) an empirical yet data-driven estimate of correction factors for ethnic variability selected as follows: Caucasians Ͼ75% of births; Hispanic Ͼ40%; African-American Ͼ40%, and Asian/Pacific Ͼ50% (2004 ethnic distribution from http://www2.uthscsa.edu/ nnsis/). These modifiers are used to define ethnically adjusted rates of detection for conditions with emerging evidence of broad, racially defined incidence rates (table 1) , beyond the well-known clustering of specific conditions Rinaldo/Lim/Tortorelli/Gavrilov/Matern in small enclaves [21, 22] . This approach, of course, is based on the assumption of mutual compensation when applied across more than four million births in the US. Under these circumstances, a nationwide implementation of the recommended panel of 42 conditions could lead to the identification of approximately 1,600-1,700 cases per year. To date, however, the partial implementation of the ACMG panel implies that more than 180 cases could remain undetected and/or unreported. More than 50 of them would be affected with one of the primary targets, and half of them carry a risk of sudden and unexpected death [3] . In view of available evidence on the high rate of lethality at the first episode of metabolic decompensation, which could be as high as 30-50% in certain disorders of fatty acid oxidation, even under the most conservative scenario as many as ten infants born in the United States this year are at risk of dying because they are affected with a treatable condition not yet included in a state newborn screening panel.
As mentioned above, most of the secondary targets are part of the differential diagnosis of one or more conditions in the core panel. Furthermore, it has become increasingly apparent that there are additional conditions potentially detectable by analysis of the same amino acid and acylcarnitine markers [23] [24] [25] . This observation suggests a need in the near future to update the list of secondary targets, and possibly upgrade a few of the existing ones to a status of primary target on the basis of new evidence obtained after the implementation of expanded screening by MS/MS [26] . Table 2 summarizes these emerging conditions, their respective informative markers, and the number of cases known to us as a result of data collection in the context of a collaborative project which has grown to include 82 laboratories worldwide (see www.region4genetics.org).
Although much progress has taken place recently, a large number of other conditions are still actively being considered for future expansion of newborn screening programs. Table 3 is a representative, but likely incomplete, list of conditions currently being considered. Analytical development of screening tests and clinical validation through prospective pilot studies for many of them are in progress. For example, our laboratory is actively involved in three projects, namely screening for lysosomal storage diseases [27, 28] , Wilson disease [29] , and X-linked adrenoleukodystrophy [30] . In anticipation of the outcome of several ongoing projects, the Secretary Advisory Committee on Heritable Disorders and Genetic Diseases in Newborn and Children (ACHDGDNC; http://mchb.hrsa.gov/programs/genetics/committee/) has developed a process for the nomination of conditions to be considered for inclusion in the uniform panel, which is based on sequential stages of administrative review, committee approval to proceed, and appointment of an evidence review group (ERG). The charge of the ERG is to assess all available evidence and make recommendations back to ACHDGDNC. In case of a positive outcome, a recommendation could be made to add the approved condition to the uniform panel [31] . However, it is likely that a vigorous, iterative process will first take place to address gaps in the understanding of the natural history of the condition, and the availability of clinical validation data, which must include a prospective pilot study and modality, efficacy, and availability of treatment options. More information on the nomination process, which was launched on June 22, 2007, can be found at the website listed above. Based on anecdotal information, it appears more than likely that several conditions will be nominated formally in the near future, with a review process taking place between 2008 and 2009. 
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Discussion
Dr. Koletzko: Tandem screening was introduced in Bavaria in January 1999 and we are just as enthusiastic and consider this a quantum leap in the early detection of disease, not only because we have a larger number of diagnoses. It is also important in that the diagnosis has become far more precise and there are much fewer false-positive results. With respect to newborn screening I really wonder whether the motto the bigger the better is always true; whether the longer list is always the better list. The longer list obviously is of greater advantage if we talk about research applications. It is also of greater advantage if we try to diagnose symptomatic patients, then the more we can detect will give us a greater likelihood of making a diagnosis. But from the European perspective screening is really a public health concept that should be offered to all newborns in a nation regardless of where they are born. Then there is not only the question of benefit, there is also the question of harm and not to do harm will be the guiding principle. From that point of view in our country we feel that analytical methodology is only one part of the concept. In addition to a good analytical tool, it is very important that a tracking system is established to monitor and find those who have not been screened, and also to make sure that those who have been screened and have a positive result are really followed up. Experience has shown that without a tracking system a lot of problems occur. The other concern is that one would not want to introduce detection of disorders where there is no true benefit for the child. For example organic acidemias; the link has been made between the biochemical abnormality and 3-methylcrotonyl-CoA carboxylase (3MCC) deficiency. In the literature there are a number of symptomatic patients with that biochemical abnormality, but the experience of the last 8 years has shown that most children affected by 3MCC deficiency in the newborn screening don't have any disease. So there is no benefit from screening for this deficiency. The same is true with newborn screening for hypercholesterolemia, there is really no benefit. Obviously, yes, we want to detect those with primary genetic hypercholesterolemia but when is the right time? Is newborn screening really the right time or is it the right time when you can't intervene?. If you make a diagnosis and cannot offer anything to the family in terms of treatment for a newborn, then I think the adverse effects need to be considered. Adrenoleukodystrophy is the same, it can be diagnosed, and there may be some benefit from prenatal diagnosis in a sibling, but there is no agreement that treatment is really beneficial. This needs to be looked at more closely and I could not agree with you more in terms of research or evaluation that the list should be enlarged, but in terms of implementation of public health service, that needs to be thoroughly discussed.
Dr. Rinaldo: The point is actually not about 3MCC, it is about the same marker being diagnostic for six different conditions. The diagnoses of HMG-CoA lyase deficiency or ␤-ketothiolase or 3-methylglutaconic aciduria must be clearer. We can have long discussions about the fact that it goes back to the environment and the modifiers; I have seen comatose patients with 3MCC. There is beautiful paper in the American Journal of Human Genetics, well-presented data, and yet not a single word about the differential diagnosis of 3MCC, and that is a problem. The point is what about those patients. To say that there are adverse effects is highly questionable. In fact it is mostly anecdotal based on a single case; so we really have to keep things in a perspective. 3MCC could be asymptomatic for a long time, in fact maternal cases have been diagnosed. Yet under the right circumstances it could even be a life-threatening disease. We just don't know what makes the difference between the two scenarios. The same goes for excluding propionic acidemia and methylmalonic acidemia, conditions that nobody should doubt, as presented earlier by Dr. Berry, because they can cause life-threatening episodes and serious damage and pancreatitis. To deny a patient the Rinaldo/Lim/Tortorelli/Gavrilov/Matern best possible chance of being treated in the best possible way is just against every fiber of my body and everything I believe in. The point is a public policy cannot be generalized so that it compromises the chances of individual patients to be treated in the best possible way. It is not a decision for politicians or policy makers, it is a decision for the individual families and their physician. What is best; we need the information; we need to know.
Dr. Lagercrantz: Why do people still continue to collect blood from the heel of babies? In Sweden we take a venous sample; it is much less painful and you can get much more blood [1] .
Dr. Rinaldo: An excellent point and there is really no good reason to continue to do it this way.
Dr. Strandvik: I want to support what Dr. Koletzko said. As a clinician I have seen dramatic pathology in the relation between mother and child when a diagnosis is made very early or if formation is obtained about something which sometimes won't result in a clinical disease for many years. In these cases, many parents become hesitant to bond to the child because they are afraid of losing it. The first period in a small infant's life is extremely important for this bonding [2] . When you show such a high percentage of positive results with this enormous tandem spectrometry, indicating a lot of diseases, do you give psychological support for all this or how do you handle it?
Dr. Rinaldo: It really should be mentioned that human screening is not a test, it is a system that includes various components such as evaluation and follow-up and support. It is interesting though that although we seem to be so focused on the potential negative consequences of a diagnosis of a known condition, nobody really talks about the real problem: false-positives. The acceptability of screening could be greatly improved if we reduced the false-positives. That is why in our collaborative project we have performance metrics and we say that if a program has a false-positive regulator of more than 0.3% by tandem mass spectrometry then there is a problem, and yet there are programs with a false-positive rate of 1-2%. That is really why we are teaching pediatricians to start asking tough questions because it is probably not helpful to know what the sensitivity or the specificity of a system is overall. If you ask what the positive predictive value is, I can probably answer that mine is 47% over 4 years, meaning that 1 in every 2 that I report as abnormal is real. In most cases the false-positive predictive value will be a single digit, meaning that for every 1 shown positive there will be 20 false-positives. With a low positive predictive value, a lot of downstream problems and issues are actually being created with acceptance of testing and disattached parents. Waisbren et al. [3] have published a beautiful paper showing the number of hospitalizations, visits to the emergency room and all sorts of problems in families of children who are false-positive. So the point is, bigger might not be better if it isn't handled well. If it is done well, if the performance metrics are kept in check, then it is very powerful. There will always be exceptions; there will always be situations where people may object. Do you want to know at birth about the risk of heart disease; do you want to know at birth that your teenage child will be in a wheelchair; it is an incredibly tough question. Again the hope is that if you pick them up early, there will be a better outcome, and there is only one way to find out.
Dr. Berry: Actually we need to think about this in a different way, some more to immunization, especially if other genetic diseases are screened for in the future. From a public health point of view, it is just may be economically so much more advantageous to screen in the newborn period for adult-onset diseases and multifactorial complex genetic diseases that it overweighs any ideas to the contrary. It may be necessary for countries to come to grips with the idea that newborn screening to identify disorders that aren't present in newborn period may be better for the common good; that actually a greater number of individuals may be helped while, at the same time, there are psychological problems that occur to a minority. Perhaps it is just only financially feasible to do this in the newborn period, and so some difficult decisions might need to be made in the future.
Dr. Rinaldo: I could not agree more. In fact I hope I didn't give anybody the impression that all this is black and white and clear cut, it is incredibly complex. But you are right, even Minnesota will screen 75,000 babies, 99.5% coming from 118 birthing places, so the collection is centralized. The moment you lose the opportunity to do something in an existing system that is really focused on a relatively small number of sites where the specimens are procured, and you start going to the individual doctors' offices then you start going into the tens of thousands. The old systems, especially when it comes to fairness and universality, are almost impossible to comply with. That is actually a very good point, for the greater good the newborn screening card has a massive potential. Under certain circumstances, in some cases, that again could have perceived negative consequences, but the greater of good would be well served.
